| Citation: |
LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
|
To investigate the causal association between 91 kinds of circulating inflammatory proteins and different subtypes of breast cancer (estrogen receptor-positive and -negative breast cancer) using a two-sample Mendelian randomization (MR) method.
Corresponding exposure and outcome data were extracted from the genome-wide association study database. The data were analyzed by two-sample MR with inverse-variance weighting (IVW) as the primary study method, and MR-Egger, weighted median, simple mode, and weighted mode were used to complement the results. The results were complemented by sensitivity analysis to verify the reliability of the data.
The IVW results showed that SULT1A1 (P=0.0007) was associated with an increased risk of total BC, whereas IL-5 (P=0.0011) was associated with a decreased risk of total BC. SULT1A1 (P=0.0011) and CX3CL1 (P=0.0005) were associated with an increased risk of ER+BC, whereas beta-NGF (P=0.0001) was associated with an increased risk of ER−BC. Supplementary analysis methods validated that the findings were consistent in direction and magnitude. The results of the sensitivity analysis showed that the data were reliable and unbiased.
Using the MR method, this study confirms that SULT1A1 is a risk factor for overall breast cancer, whereas IL-5 is a protective factor for overall breast cancer. SULT1A1 and CX3CL1 are risk factors for estrogen receptor-positive breast cancer, and beta-NGF is a risk factor for estrogen receptor-negative breast cancer.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
|
| [2] |
Zhao JH, Stacey D, Eriksson N, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets[J]. Nat Immunol, 2023, 24(9): 1540-1551. doi: 10.1038/s41590-023-01588-w
|
| [3] |
Kehm RD, McDonald JA, Fenton SE, et al. Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research[J]. Int J Environ Res Public Health, 2020, 17(15): 5445. doi: 10.3390/ijerph17155445
|
| [4] |
Cai Y, Yousef A, Grandis JR, et al. NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer[J]. Adv Biol Regul, 2020, 75: 100653. doi: 10.1016/j.jbior.2019.100653
|
| [5] |
Danforth DN. The Role of Chronic Inflammation in the Development of Breast Cancer[J]. Cancers (Basel), 2021, 13(15): 3918. doi: 10.3390/cancers13153918
|
| [6] |
Lou MWC, Drummond AE, Swain CTV, et al. Linking Physical Activity to Breast Cancer via Inflammation, Part 2: The Effect of Inflammation on Breast Cancer Risk[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(5): 597-605. doi: 10.1158/1055-9965.EPI-22-0929
|
| [7] |
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023[J]. Wellcome Open Res, 2019, 4: 186. doi: 10.12688/wellcomeopenres.15555.1
|
| [8] |
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement[J]. JAMA, 2021, 326(16): 1614-1621. doi: 10.1001/jama.2021.18236
|
| [9] |
Mercer KE, Apostolov EO, Gamboa da Costa G, et al. Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis[J]. Int J Mol Epidemiol Genet, 2010, 1(2): 92-103.
|
| [10] |
Shi L, Shen W, Davis MI, et al. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers[J]. Nat Cancer, 2023, 4(3): 365-381. doi: 10.1038/s43018-023-00523-0
|
| [11] |
Sak K, Everaus H. Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids[J]. Curr Drug Metab, 2016, 17(6): 528-541. doi: 10.2174/1389200217666160219113924
|
| [12] |
Forat-Yazdi M, Jafari M, Kargar S, et al. Association between SULT1A1 Arg213His (rs9282861) Polymorphism and Risk of Breast Cancer: A Systematic Review and Meta-Analysis[J]. J Res Health Sci, 2017, 17(4): e00396.
|
| [13] |
Krantz D, Mints M, Winerdal M, et al. IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity[J]. Scand J Immunol, 2020, 92(6): e12926. doi: 10.1111/sji.12926
|
| [14] |
Quail DF, Olson O, Bhardwaj P, et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF[J]. Nat Cell Biol, 2017, 19(8): 974-987.
|
| [15] |
Lee EJ, Lee SJ, Kim S, et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression[J]. Cell Signal, 2013, 25(10): 2025-2038. doi: 10.1016/j.cellsig.2013.06.004
|
| [16] |
Liu G, Chen XT, Zhang H, et al. Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients[J]. Front Oncol, 2022, 12: 1019247. doi: 10.3389/fonc.2022.1019247
|
| [17] |
Korbecki J, Simińska D, Kojder K, et al. Fractalkine/CX3CL1 in Neoplastic Processes[J]. Int J Mol Sci, 2020, 21(10): 3723. doi: 10.3390/ijms21103723
|
| [18] |
Geismann C, Erhart W, Grohmann F, et al. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines[J]. Int J Mol Sci, 2018, 19(6): 1661. doi: 10.3390/ijms19061661
|
| [19] |
Ren F, Zhao Q, Huang L, et al. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas[J]. Immunol Cell Biol, 2019, 97(5): 457-469. doi: 10.1111/imcb.12225
|
| [20] |
Conroy MJ, Lysaght J. CX3CL1 Signaling in the Tumor Microenvironment[J]. Adv Exp Med Biol, 2020, 1231: 1-12.
|
| [21] |
Liang Y, Yi L, Liu P, et al. CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway[J]. J Cancer, 2018, 9(19): 3603-3612. doi: 10.7150/jca.26497
|
| [22] |
Dreyer TF, Kuhn S, Stange C, et al. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo[J]. Cancer Immunol Res, 2021, 9(7): 779-789. doi: 10.1158/2326-6066.CIR-20-0327
|
| [23] |
Tiberi A, Carucci NM, Testa G, et al. Reduced levels of NGF shift astrocytes toward a neurotoxic phenotype[J]. Front Cell Dev Biol, 2023, 11: 1165125. doi: 10.3389/fcell.2023.1165125
|
| [24] |
Davidson B, Reich R, Lazarovici P, et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma[J]. Breast Cancer Res Treat, 2004, 83(2): 119-128. doi: 10.1023/B:BREA.0000010704.17479.8a
|
| [25] |
Noh SJ, Bae JS, Jamiyandorj U, et al. Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients[J]. BMC Cancer, 2013, 13: 516. doi: 10.1186/1471-2407-13-516
|
| [26] |
Jung HH, Kim JY, Cho EY, et al. Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy[J]. Cancers (Basel), 2021, 13(21): 5260. doi: 10.3390/cancers13215260
|
| [27] |
Bruno F, Arcuri D, Vozzo F, et al. Expression and Signaling Pathways of Nerve Growth Factor (NGF) and Pro-NGF in Breast Cancer: A Systematic Review[J]. Curr Oncol, 2022, 29(11): 8103-8120. doi: 10.3390/curroncol29110640
|
| [1] | ZHOU Xinying, ZHANG Hu, DAI Haiyan. Mendelian Randomization Analysis of Correlation Between Interleukin and Risk of Gynecological Tumors[J]. Cancer Research on Prevention and Treatment, 2025, 52(6): 511-519. DOI: 10.3971/j.issn.1000-8578.2025.24.0994 |
| [2] | HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438 |
| [3] | HU Di, SHUI Yifang, MIAO Keke, LI Mengquan. Mendelian Randomized Study of Protective Effect of Statins on Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 165-171. DOI: 10.3971/j.issn.1000-8578.2025.24.0654 |
| [4] | YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153 |
| [5] | GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284 |
| [6] | LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037 |
| [7] | WANG Jiaqi, TANG Wei, HUANG Xiao, FU Deyuan. Causal Association Between Omega-3 Fatty Acids and Risk of Breast Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 567-572. DOI: 10.3971/j.issn.1000-8578.2024.23.1053 |
| [8] | WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125 |
| [9] | WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507 |
| [10] | WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411 |
Figures(5)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: